For tau pathology, alterations in WM integrity were observed in a transgenic mouse model of fibrillar tau (22, 23), preceding the emergence of tau pathology (22), with clinical investigations suggesting a role of WM hyperintensities in tau pathology in the AD spectrum (24). This evidence concerns the gene MAPT and Alzheimer disease.